Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Change in Cash (2019 - 2025)

Addex Therapeutics' Change in Cash history spans 7 years, with the latest figure at $604.8 billion for Q2 2025.

  • On a quarterly basis, Change in Cash fell 73.05% to $604.8 billion in Q2 2025 year-over-year; TTM through Jun 2025 was -$624.1 billion, a 78.07% increase, with the full-year FY2025 number at -$2.0 million, down 182.69% from a year prior.
  • Change in Cash came in at $604.8 billion for Q2 2025, up from -$556.9 billion in the prior quarter.
  • The five-year high for Change in Cash was $2244.6 billion in Q2 2024, with the low at -$2764.5 billion in Q3 2023.
  • Historically, Change in Cash has averaged -$168.7 billion across 5 years, with a median of -$3.2 million in 2021.
  • Peak annual rise in Change in Cash hit 6956494.28% in 2023, while the deepest fall reached 178140123.19% in 2023.
  • Year by year, Change in Cash stood at $1.9 million in 2021, then crashed by 823.36% to -$14.0 million in 2022, then soared by 75.18% to -$3.5 million in 2023, then skyrocketed by 82.87% to -$597015.9 in 2024, then skyrocketed by 101305192.64% to $604.8 billion in 2025.
  • Business Quant data shows Change in Cash for ADXN at $604.8 billion in Q2 2025, -$556.9 billion in Q1 2025, and -$597015.9 in Q4 2024.